Among those, isolated swelling of the lower leg was most often indicated by them (58.8%). Swollen and painful legs were reported by three travelers (17.6%). One traveler reported swollen legs in combination with dyspnea with or without circulatory troubles, isolated painful legs or paresthesia in the legs. However, none of the symptomatic travelers reported that

VTE was confirmed by their physician. We received answered Q2 and Q3 of 236 travelers enabling us to compare the recommended and actually performed TP. According to the calculated model I, the TR of the traveler had a significant influence (p < 0.001) on the recommended TP. The kind and duration of travel were no significant Bortezomib price variables in this model. It also makes no difference, if the confounder is contributed in the model or not, so sex had no relevant effect on the relationship between recommended TP and the TR. In the calculated model II, we searched for significant

influences on the performed TP. The TR of the traveler (p < 0.001) and additionally, the time being seated during travel as given by the travelers in Q3 (p = 0.0034 with confounders/p = 0.0028 without confounders) showed a significant effect. The kind of travel was no relevant variable. The confounder sex also had no effect. For both models, the results were similar when using either the Vienna24 or Hall25 recommendation for the classification of the TR. The results of model III showed a significant association between the recommended and actually performed TP (p < 0.001). The confounder's HSP inhibitor drugs sex and TR did not change this result. Cross-tabulating to further analyze the relationship between recommended and performed TP resulted in a kappa coefficient of 0.54 which argues for a moderate agreement. Figure 5 compares the distribution of the recommended Arachidonate 15-lipoxygenase and performed TP. This was further underlined by the calculated CC of 0.699. However, more travelers than recommended performed a specific TP (49.6% vs 39.8%). This was mainly done by an increased intake of ASA alone

or in combination with stockings. In summary, only 6.4% of the physicians recommended the intake of ASA whereas 19.1% of the travelers used ASA during their LHT. Still facing the lack of evidence-based recommendations for the prevention of TT, it is of interest how travelers and physicians cope with this unpleasant situation. To our knowledge, our study was the first focusing on this matter. Overall, the three most important findings of our study are: Travelers of both sexes are well aware of the risk of TT during LHT. Especially travelers aged 60 years and above were well informed about the risk of TT. Air travel was estimated to be the kind of travel with the highest risk of TT. Current data, however, are somehow conflicting whether the risk of TT is indeed higher for air travel compared to other means of transport.